Metabolomics analysis of type 2 diabetes remission identifies 12 metabolites with predictive capacity: a CORDIOPREV clinical trial study

Marina Mora-Ortiz,Juan F. Alcala-Diaz,Oriol Alberto Rangel-Zuñiga,Antonio Pablo Arenas-de Larriva,Fernando Abollo-Jimenez,Diego Luque-Cordoba,Feliciano Priego-Capote,Maria M. Malagon,Javier Delgado-Lista,Jose M. Ordovas,Pablo Perez-Martinez,Antonio Camargo,Jose Lopez-Miranda
DOI: https://doi.org/10.1186/s12916-022-02566-z
IF: 9.3
2022-10-29
BMC Medicine
Abstract:Type 2 diabetes mellitus (T2DM) is one of the most widely spread diseases, affecting around 90% of the patients with diabetes. Metabolomics has proven useful in diabetes research discovering new biomarkers to assist in therapeutical studies and elucidating pathways of interest. However, this technique has not yet been applied to a cohort of patients that have remitted from T2DM.
medicine, general & internal
What problem does this paper attempt to address?